Uveitic Macular EdemaPhase 1/2NCT00958906
Pilot Study for the Evaluation of Intravitreal Infliximab in the Treatment of Uveitic Macular Edema
A Phase 1/2 study testing Infliximab (intravitreal, 2.0mg/0.05ml) in people with Uveitic Macular Edema and Intraocular Inflammation, run by Icahn School of Medicine at Mount Sinai at 1 site in United States.
Trial summary
The purpose of this study is to determine if intravitreal infliximab is a safe and effective treatment for macular edema secondary to uveitis. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Uveitic Macular Edema, Intraocular Inflammation
- What is being tested?
- Infliximab (intravitreal, 2.0mg/0.05ml)
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 10 participants
- Where
- 1 siteUnited States
- Study dates
- Aug 2009to Oct 2009
- Phase
- Phase 1/2
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Participant must be 18 years of age or older.
- Participant must understand and sign the protocol's informed consent document.
- Participants must have uveitic macular edema in one eye as defined by all of the following criteria:
- Presence of active intermediate uveitis or posterior uveitis.
- Macular edema defined as a central macular thickness of ≥ 250 μm on OCT.
- Uveitis must be noninfectious as determined by standard investigations used in the diagnostic investigation of uveitis.
Show all 9Show fewer
- Participant must have visual acuity between 20/40 and hand motions in the study eye.
- Participant must have a steady fixation in the study eye and media clear enough for good quality imaging.
- Female participants of childbearing potential must not be pregnant or breast-feeding, must have a negative pregnancy test at screening and must practice an adequate method of birth control. Males able to father a child must agree to practice birth control. Acceptable methods of birth control include hormonal contraception (birth control pills, injected hormones or vaginal ring), intrauterine device, barrier methods with spermicide (diaphragm with spermicide, condom and spermicide) or surgical sterilization (hysterectomy, tubal ligation or vasectomy in a partner). If a participant is of childbearing potential, she must be willing to undergo monthly urine pregnancy tests. Both males and females must agree to use adequate birth control for three months after the intravitreal infliximab injection.
Who cannot join
- Participant is in another investigational study and actively receiving study therapy.
- Participant is unable to comply with study procedures or follow-up visits.
- Participant has uveitic macular edema (as defined above) in both eyes.
- Participant has multiple sclerosis or symptoms suggestive of multiple sclerosis.
- Participant has evidence of ocular disease other than uveitis in either eye that may confound the outcome of the study (e.g., diabetic retinopathy, age-related macular degeneration, vitreomacular traction, moderate/severe myopia, etc.).
- Participant is expected to need ocular surgery in the study eye during the course of the study.
Show all 13Show fewer
- Participant has undergone ocular surgery or an intravitreal/periocular steroid injection in the study eye within the past 3 months.
- Participant has had a YAG laser capsulotomy or intravitreal anti-VEGF treatment in the study eye within the past 6 weeks.
- Participant has had a pars plana vitrectomy in the study eye.
- Participant is on ocular or systemic medications known to be toxic to the lens, retina, or optic nerve.
- Participant with a history of ocular herpes simplex virus infection in the study eye.
- A condition that, in the opinion of the investigator, would preclude participation in the study (e.g., unstable medical status including blood pressure and glycemic control).
- There are no criteria for inclusion/exclusion for the fellow eye. Only one eye can have macular edema in order for the potential participant to be considered for enrollment.
Trial locations and contacts
1 site in 1 country.
United States1 site
Department of Ophthalmology, Mount Sinai School of Medicine
New York, New York, 10029
About this study
The purpose of this study is to determine if intravitreal infliximab is a safe and effective treatment for macular edema secondary to uveitis.
Read the detailed description
Participants with uveitic macular edema will be treated with one injection of intravitreal infliximab (2.0mg/0.05ml) and followed for three months. Outcomes that be assessed include best-corrected visual acuity, macular thickness as measured by optical coherence tomography, and electroretinogram responses.
- Conditions
- Uveitic Macular Edema, Intraocular Inflammation
- Being tested
- Infliximab (intravitreal, 2.0mg/0.05ml)
- Keywords
- Infliximab, Uveitis, Macular Edema, Intraocular Inflammation
- Medical subject headings
- Uveitis, Macular Edema
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Infliximab (intravitreal, 2.0mg/0.05ml)Drug
Also called Remicade™
One injection of intravitreal infliximab (2.0mg/0.05ml).
| Study group | Role | What they receive |
|---|---|---|
| Intravitreal infliximab | Experimental | Not described Receives: Drug: Infliximab (intravitreal, 2.0mg/0.05ml) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Best-corrected visual acuity
Measured: Three months
Secondary outcomes (1)
Macular thickness
Measured: One, two, and three months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Aug 2009 (estimated)
- Study startAug 2009
- Study completionOct 2009
Why it stopped: PI left institution (there are no data results for this study)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (4)Papers the sponsor has linked to this study.
- Other trials for Uveitic Macular EdemaStudies of the same condition, open and under way.
- More trials run by Icahn School of Medicine at Mount SinaiThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1/2
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 10 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Sponsor type
- University, hospital or other
- Investigators
- Farzin Forooghian, MD, Principal investigator, Icahn School of Medicine at Mount Sinai
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00958906
- Sponsor's protocol ID
- GCO # 09-0611
- Status last verified
- Jun 2011
- First submitted
- 11 Aug 2009
- Last updated
- 23 Jun 2011
- Results posted
- No
- Data monitoring committee
- No
Publications
Theodossiadis PG, Liarakos VS, Sfikakis PP, Vergados IA, Theodossiadis GP. Intravitreal administration of the anti-tumor necrosis factor agent infliximab for neovascular age-related macular degeneration. Am J Ophthalmol. 2009 May;147(5):825-30, 830.e1. doi: 10.1016/j.ajo.2008.12.004. Epub 2009 Feb 10.
PubMed 19211094Theodossiadis PG, Liarakos VS, Sfikakis PP, Charonis A, Agrogiannis G, Kavantzas N, Vergados IA. Intravitreal administration of the anti-TNF monoclonal antibody infliximab in the rabbit. Graefes Arch Clin Exp Ophthalmol. 2009 Feb;247(2):273-81. doi: 10.1007/s00417-008-0967-4. Epub 2008 Nov 4.
PubMed 18982345Giansanti F, Ramazzotti M, Vannozzi L, Rapizzi E, Fiore T, Iaccheri B, Degl' Innocenti D, Moncini D, Menchini U. A pilot study on ocular safety of intravitreal infliximab in a rabbit model. Invest Ophthalmol Vis Sci. 2008 Mar;49(3):1151-6. doi: 10.1167/iovs.07-0932.
PubMed 18326743Olson JL, Courtney RJ, Mandava N. Intravitreal infliximab and choroidal neovascularization in an animal model. Arch Ophthalmol. 2007 Sep;125(9):1221-4. doi: 10.1001/archopht.125.9.1221.
PubMed 17846362